JP2018522894A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522894A5
JP2018522894A5 JP2018503533A JP2018503533A JP2018522894A5 JP 2018522894 A5 JP2018522894 A5 JP 2018522894A5 JP 2018503533 A JP2018503533 A JP 2018503533A JP 2018503533 A JP2018503533 A JP 2018503533A JP 2018522894 A5 JP2018522894 A5 JP 2018522894A5
Authority
JP
Japan
Prior art keywords
trehalose
melibiurose
cordobiose
gentiobiulose
rutinulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018503533A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018522894A (ja
JP6448847B2 (ja
Filing date
Publication date
Priority claimed from EP15177544.2A external-priority patent/EP3120842A1/en
Application filed filed Critical
Publication of JP2018522894A publication Critical patent/JP2018522894A/ja
Publication of JP2018522894A5 publication Critical patent/JP2018522894A5/ja
Application granted granted Critical
Publication of JP6448847B2 publication Critical patent/JP6448847B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018503533A 2015-07-20 2016-07-19 腹膜治療液及び腹膜治療液容器 Active JP6448847B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15177544.2 2015-07-20
EP15177544.2A EP3120842A1 (en) 2015-07-20 2015-07-20 Peritoneal therapeutic fluid
PCT/EP2016/067186 WO2017013120A1 (en) 2015-07-20 2016-07-19 Peritoneal therapeutic fluid

Publications (3)

Publication Number Publication Date
JP2018522894A JP2018522894A (ja) 2018-08-16
JP2018522894A5 true JP2018522894A5 (cg-RX-API-DMAC7.html) 2018-12-13
JP6448847B2 JP6448847B2 (ja) 2019-01-09

Family

ID=53785450

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018503533A Active JP6448847B2 (ja) 2015-07-20 2016-07-19 腹膜治療液及び腹膜治療液容器

Country Status (23)

Country Link
US (2) US20180221303A1 (cg-RX-API-DMAC7.html)
EP (2) EP3120842A1 (cg-RX-API-DMAC7.html)
JP (1) JP6448847B2 (cg-RX-API-DMAC7.html)
KR (2) KR102266889B1 (cg-RX-API-DMAC7.html)
CN (2) CN110075307A (cg-RX-API-DMAC7.html)
AU (1) AU2016296216B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018001005B1 (cg-RX-API-DMAC7.html)
CA (1) CA2990532C (cg-RX-API-DMAC7.html)
CO (1) CO2018000236A2 (cg-RX-API-DMAC7.html)
CY (1) CY1124467T1 (cg-RX-API-DMAC7.html)
DK (1) DK3324951T3 (cg-RX-API-DMAC7.html)
ES (1) ES2880796T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20211319T1 (cg-RX-API-DMAC7.html)
HU (1) HUE055208T2 (cg-RX-API-DMAC7.html)
LT (1) LT3324951T (cg-RX-API-DMAC7.html)
MX (1) MX387020B (cg-RX-API-DMAC7.html)
PL (1) PL3324951T3 (cg-RX-API-DMAC7.html)
PT (1) PT3324951T (cg-RX-API-DMAC7.html)
RS (1) RS62142B1 (cg-RX-API-DMAC7.html)
RU (1) RU2718908C2 (cg-RX-API-DMAC7.html)
SI (1) SI3324951T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202100428T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017013120A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3381484A1 (en) * 2017-03-31 2018-10-03 Opterion Health AG Carbohydrate composition for dialysis
CN108310005A (zh) * 2018-04-18 2018-07-24 浙江天瑞药业有限公司 一种抗腹膜纤维化的腹膜透析液
WO2020081654A1 (en) * 2018-10-16 2020-04-23 President And Fellows Of Harvard College Sirt1 activating compounds

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2155910C (en) * 1995-08-11 1999-12-14 George Wu Biocompatible aqueous solution for use in continuous ambulatory peritoneal dialysis
ATE366587T1 (de) * 1999-08-10 2007-08-15 Innovata Plc Verfahren für die verabreichung von heilmitteln mittels einer dextrinlösung
EP1223985B1 (en) * 1999-10-15 2005-11-30 Dow Global Technologies Inc. Dialysis solution including polyglycol osmotic agent
JP4882054B2 (ja) * 2000-09-13 2012-02-22 独立行政法人科学技術振興機構 腹膜透析液およびその調製法
US6841578B2 (en) * 2001-08-16 2005-01-11 Stephen T. Sonis Treatment and prevention of mucositis in cancer patients
GB0200704D0 (en) * 2002-01-14 2002-02-27 Britannia Pharmaceuticals Ltd Use of phospholipids in peritoneal dialysis
ITRM20020562A1 (it) * 2002-11-06 2004-05-07 Sigma Tau Ind Farmaceuti Uso del resveratrolo per la preparazione di un medicamento utile per il trattamento delle infezioni da virus dell'influenza.
SE524530C2 (sv) * 2002-12-10 2004-08-24 Gambro Lundia Ab Metod för att framställa en medicinsk lösning för peritonealdialys där en lösning innehållandes ett eller flera acetylerade eller deacetylerade aminosocker värme- eller strålningssteriliseras med bestämda pH-värden och med bestämda viktsprocent för att undvika att cytotoxiska produkter bildas.
EP1684772A1 (en) * 2003-11-17 2006-08-02 Braintree Laboratories, Inc. Therapeutic peg solution concentrate
US7498341B2 (en) 2004-01-31 2009-03-03 Sanofi Aventis Deutschland Gmbh Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
US7384558B2 (en) 2004-07-26 2008-06-10 Baxter International Inc. Compositions capable of inhibiting reactive oxygen and carbonyl species
US20060292099A1 (en) * 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
EP1993522A2 (en) 2005-10-26 2008-11-26 Kao Corporation Resveratrol and/or grape leaf extract as i.a. endurance improver, anti-aging agent, muscle strength improver
JP2010535221A (ja) * 2007-07-31 2010-11-18 イーエルシー マネージメント エルエルシー レスベラトロール誘導体を含有する化粧用組成物
US20090035240A1 (en) * 2007-07-31 2009-02-05 Maes Daniel H Aqueous Based Cosmetic Compositions Containing Resveratrol Derivatives And An Aqueous Phase Structuring Agent
CN102264348A (zh) * 2008-11-26 2011-11-30 脂蛋白技术有限公司 生物活性提高的白藜芦醇制剂
EP2381935B1 (en) * 2009-01-19 2016-06-01 Lycored Ltd. Synergistic combinations of carotenoids and polyphenols
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
ES2365429B1 (es) * 2010-03-05 2012-09-06 Universidad De Castilla De La Mancha Solucion para dialisis peritoneal
EP2609918A1 (en) * 2011-12-27 2013-07-03 Zytoprotec GmbH Peritoneal dialysis fluid comprising a GSK-3 inhibitor
MX2014012942A (es) * 2012-04-24 2015-02-10 Univ British Columbia Dialisato a base de polimero.
EP2695606A1 (en) * 2012-08-09 2014-02-12 ETH Zürich Liposome composition for peritoneal dialysis
ITRM20130135A1 (it) * 2013-03-06 2014-09-07 Michele Azzolini Nuovi derivati del resveratrolo.
CN103330715B (zh) * 2013-07-01 2015-09-02 华仁药业股份有限公司 一种抗腹膜纤维化的腹膜透析液

Similar Documents

Publication Publication Date Title
BR112018001572A2 (pt) método para induzir uma resposta imune, antígeno, adenovírus, uso de um antígeno e de um adenovírus, e, polinucleotídeo.
BR112016015422A2 (pt) formulações de vacina de frasco único
EA201490610A1 (ru) Соединения и способы усиления врожденных иммунных ответов
CL2010000520A1 (es) Forma cristalina del propanoato de (s) - isopropil 2 -(((s) - (((2r,3r,4r,5r) - 5- (2,4-dioxo-3,4-dihidropirimidim-1(2h) -il)-4-fluoro-3-hidroxi-4-metitetrahidrofuran-2-il)metoxi)(fenoxi)fosforil)amino); proceso de preparacion; composicion framaceutica; y su uso para el tratamiento de una infeccion causada por el virus de la hepatitis c.
EA201590890A1 (ru) Производные 5-фтор-n-(пиридин-2-ил)пиридин-2-амина, содержащие сульфоксиминовую группу
MA38675A1 (fr) Dérivés de nucléosides 4'-fluoro-2'-méthyle substitués utiles pour inhiber la replication de l'hepatite c (hcv)
EA201892735A1 (ru) Состав вакцины против hiv
HK1257628A1 (zh) 治療沙粒病毒科和冠狀病毒科病毒感染的方法
EA201491754A1 (ru) Вакцина против rsv
AR092401A1 (es) Formulaciones de anticuerpos anti-receptor de prolactina (anti-prlr)
HRP20201078T1 (hr) Pripravci namijenjeni moduliranju eksprimiranja sod-1
JP2018522894A5 (cg-RX-API-DMAC7.html)
EA201001491A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
MX393384B (es) Adyuvantes sinteticos de glucopiranosil-lipido.
NO20090194L (no) Rekombinant viral vaksine
EP2268288A4 (en) NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF CALICIVIRIDAE INFECTIONS, INCLUDING NOROVIRUS INFECTIONS
FI2504353T4 (fi) Lipopeptidikoostumukset ja vastaavat menetelmät
EA201791903A1 (ru) β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-C-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ
MX378901B (es) Formulaciones liquidas estables de virus de vacuna.
EA201391495A1 (ru) Производные пиримидина для лечения вирусных инфекций
BR112016013714A8 (pt) compostos cristalinos de análogos de sofosbuvir antivirais, uso dos mesmos e composição farmacêutica
BR112019010275A2 (pt) adenovírus recombinante, composição, uso do adenovírus ou composição, método de induzir uma resposta imune em um paciente, e, adenovírus de símio não humano
EP2854865A4 (en) METHOD FOR THE TREATMENT OF METABOLIC SYNDROME BY MODULATION OF THE HEAT SHOCK PROTEIN (HSP) 90-BETA
EA200970247A1 (ru) Способ получения оптического активного n-защищенного 3-аминопирролидина или оптически активного n-защищенного 3-аминопиперидина и соответствующих кетонов путем оптического разделения рацемических смесей аминов с использованием бактериальной омега-трансаминазы
EA201891666A1 (ru) Арилзамещенные пиримидины для применения при инфекции, вызванной вирусом гриппа